Opko will use the proceeds to fund R&D to further develop its diagnostics and pharmacy portfolio, and for working capital including debt repayment.
The test, for use on the Claros I Analyzer, leverages microfluidic technology in a disposable test cassette to provide results in 10 minutes or less.
The non-coverage decision came despite appeals by the company following a draft non-coverage determination issued last year.
Veracyte was the only company in the 360Dx Index whose stock price rose last month while NantHealth, NeoGenomics, and Accelerate Diagnostics saw sharp declines.
Both Opko and Phillip Frost will pay penalties and refrain from certain activities. Frost had been accused by the SEC of participating in market manipulation schemes.
The company's $249.8 million in revenues missed the consensus Wall Street estimate, but its loss of $.05 per share beat analysts' average expectation.
The stock prices for 14 companies in the 360Dx Index were down during the month, while 13 firms' share prices fell.
The company was hit with an SEC lawsuit last week and said it expects the Nasdaq matter to be "resolved favorably" but it cannot estimate when trading will resume.
In its response, the company accused the Securities and Exchange Commission's lawsuit of containing "serious factual inaccuracies."